These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35849723)

  • 1. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study.
    Tun AM; Khurana A; Mwangi R; Link BK; Wang Y; Feldman AL; Thompson CA; Novak AJ; Villasboas JC; Thanarajasingam G; Farooq U; Syrbu S; Nowakowski GS; Witzig TE; Ansell SM; Rimsza LM; Cerhan JR; Habermann TM; Maurer MJ
    Blood Adv; 2022 Sep; 6(17):5210-5221. PubMed ID: 35849723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
    Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
    J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
    Williams ME; Hong F; Gascoyne RD; Wagner LI; Krauss JC; Habermann TM; Swinnen LJ; Schuster SJ; Peterson CG; Sborov MD; Martin SE; Weiss M; Ehmann WC; Horning SJ; Kahl BS
    Br J Haematol; 2016 Jun; 173(6):867-75. PubMed ID: 26970533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder.
    Nie G; Sun L; Zhang C; Yuan Y; Mao H; Wang Z; Li J; Duan S; Xing C; Zhang B
    Front Immunol; 2022; 13():903315. PubMed ID: 36172352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
    Poddubnaya IV; Alekseev SM; Kaplanov KD; Lukavetskyy LM; Rekhtman GB; Dolai TK; Attili VSS; Bermúdez CD; Isaev AA; Chernyaeva EV; Ivanov RA
    Hematol Oncol; 2020 Feb; 38(1):67-73. PubMed ID: 31724191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research progress on epigenetics of small B-cell lymphoma.
    Ruan X; Zhang R; Zhu H; Ye C; Wang Z; Dong E; Li R; Cheng Z; Peng H
    Clin Transl Oncol; 2022 Aug; 24(8):1501-1514. PubMed ID: 35334078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas.
    Patel N; Durkin L; Bodo J; Hsi ED
    Am J Clin Pathol; 2020 Apr; 153(5):646-655. PubMed ID: 31953940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome and prognostic factors in ocular adnexal lymphoma.
    Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
    Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
    Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
    Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoma of the ocular adnexa: A study of 353 cases.
    Ferry JA; Fung CY; Zukerberg L; Lucarelli MJ; Hasserjian RP; Preffer FI; Harris NL
    Am J Surg Pathol; 2007 Feb; 31(2):170-84. PubMed ID: 17255761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.
    Metcalf RA; Monabati A; Vyas M; Roncador G; Gualco G; Bacchi CE; Younes SF; Natkunam Y; Freud AG
    Hum Pathol; 2014 Aug; 45(8):1730-6. PubMed ID: 24925224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
    Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
    Leahy MF; Turner JH
    Blood; 2011 Jan; 117(1):45-52. PubMed ID: 20864582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.
    Pei SN; Wang MC; Ma MC; Kuo CY; Liao CK; Qiu H; Rothwell LA; Liu Y
    Sci Rep; 2021 May; 11(1):10069. PubMed ID: 33980914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.
    Al-Hamadani M; Habermann TM; Cerhan JR; Macon WR; Maurer MJ; Go RS
    Am J Hematol; 2015 Sep; 90(9):790-5. PubMed ID: 26096944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.